<DOC>
	<DOCNO>NCT02602756</DOCNO>
	<brief_summary>Ocular melanoma treat long time enucleation , unfavorable major impact patient 's quality life , social life , self-image , feel others live disability . As matter fact , classical radiation therapy photon accurate enough deliver sufficiently high dose eradicate melanoma without cause irreversible ocular brain complication since tumor `` relatively radio resistant `` . The possibility deliver high dos due precision proton ( `` Bragg peak '' ) allow overcome limitation . The conservative uveal melanoma treatment become standard Collaborative Ocular Melanoma Study ( COMS ) indicate equivalent rate metastasis non-impaired survival rate conservative treatment compare immediate enucleation . The quality life benefit due conservative treatment demonstrate . Protontherapy dose define empirical manner , probably excessive even apply radio-resistant tumor . In France , radiotherapy proton choroidal melanoma delivers dose 60 Gy cobalt equivalent ( 52 measure Gy , `` Physical dose '' ) 4 fraction 4 day . Referential treatment ocular melanoma ( conjunctiva ) indicate proton-therapy T1 , T2 , T3 &lt; 40 % ocular volume , T4 extra scleral extension ≤ 2mm . However , enucleation indication T3 &gt; 40 % ocular volume T4 . Our purpose override relative contraindication , choroidal melanoma volume ≥ 40 % ocular volume . As matter fact , investigator observe increase demand ophthalmologists patient perform primary enucleation . Also , last five year treatment complication improve less `` hard `` hypo fractionation ( 6.5 Gy per fraction ) equivalent local control result `` hard `` fractionation ( 13 Gy per fraction ) .</brief_summary>
	<brief_title>Study Assessing Two Models Hypofractionated Protontherapy Large Choroidal Melanomas</brief_title>
	<detailed_description>A fractioned proton-therapy treatment , dose per fraction 6.5 Gy rather 13 Gy , limit rate severity complication degrade quality life complication ( pain , diminish visual acuity ) treatment ( intra-ocular injection ... ) . In study , patient receive total dose 52 Gy four 13 Gy session standard arm eight 6.5 Gy session experimental arm . The investigator expect identical local control rate within 2 year 's time decrease rate severity severe complication due adapt fractionation ( eight session low dos instead four fraction high dos usually recommend guideline small medium melanoma ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient diagnose choroidal melanoma ophthalmologist protontherapy treatment propose multidisciplinary board meeting Patient 18 year old , male female Performance status ≤ 2 Size and/or thickness great propose protontherapy appendix indication ( tumor volume/ocular globe &gt; 40 % and/or thickness ≥ 12 mm and/or diameter ≥ 18 mm thickness ≥ 10 mm diameter ≥ 15 mm ) . Possible ophthalmological followup examination 6 month , one year , 18 month two year . No contraindication adjuvant chemotherapy Authorized technique preserve optic nerve Patient undergone require medical procedure : Ophthalmological examination Clip position Protontherapy treatment ( localization CT , first simulation , second simulation , final simulation ) Patient read information note sign consent form Exclusive iris damage Exclusive conjunctival damage First melanoma surgery Enucleation plan postprotontherapy Exentration indication Life expectancy &lt; 2 year Scleral exteriorisation &gt; 2 mm Absolute radiotherapy contraindication ( ataxiatelangiectasia ) Cancer history , except complete remission cancer 5 year , basocellular skin carcinoma completely resect , insitu carcinoma treat situ cervical epithelioma Presence metastases hepatic ( endoresection authorize )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Choroid Melanoma</keyword>
</DOC>